Back to News
Market Impact: 0.25
BioVie's Bezisterim Shows Phase 2 Signal In Long COVID; Stock Down
Source: Nasdaq
Healthcare & Biotech
BioVie announced topline results from its Phase 2 ADDRESS-LC trial of Bezisterim for neurological symptoms associated with Long COVID. The article provides no efficacy, safety, or statistical-result details, limiting assessment of the trial's commercial or valuation implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BIVI0.45
More News
- Anthropic's IPO push includes a big bet on life sciences
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Illumina CEO on Q3 Results and Business Outlook
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand